# 2017

Budapest, Hungary

I-01 Martina LiebichModelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic ApproachWednesday 10:30-12:00 |

I-02 Klaus LindauerModel SimplificationWednesday 10:30-12:00 |

I-03 Dan LiuApplication of Global Sensitivity Analysis Methods to Determine the most Influential Parameters of a Minimal PBPK Model of QuinidineWednesday 10:30-12:00 |

I-04 Rocio LledoPK/PD modelling of an anti-FcRn mAb to optimise FIM design - translation from cyno to human Wednesday 10:30-12:00 |

I-05 Florence LoingevilleUsing Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertaintiesWednesday 10:30-12:00 |

I-06 Amelia DeitchmanTigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction ModelsWednesday 10:30-12:00 |

I-07 Dominik LottTolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate Wednesday 10:30-12:00 |

I-08 Rubin LubomirovPopulation pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agentWednesday 10:30-12:00 |

I-09 Inga LudwigCorrelative analysis of response to treatment and biomarker levels in a setting with a time-to-event efficacy outcome and sparse biomarker dataWednesday 10:30-12:00 |

I-10 John C LukasOrder in patch absorption rates?Wednesday 10:30-12:00 |

I-11 Sreenath M KrishnanInfluence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survivalWednesday 10:30-12:00 |

I-12 Lei MaDupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulationWednesday 10:30-12:00 |

I-13 Vincent MadelainModeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study)Wednesday 10:30-12:00 |

I-14 Paolo MagniExecution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes areaWednesday 10:30-12:00 |

I-15 Corinna MaierRobust parameter estimation for dynamical systems from outlier-corrupted dataWednesday 10:30-12:00 |

I-16 Victor Mangas-SanjuanSemi-mechanistic Pharmacodynamic model of complex receptor-hormone dynamicsWednesday 10:30-12:00 |

I-17 Ben MargettsModelling Cytomegalovirus Growth Kinetics in Immunocompromised ChildrenWednesday 10:30-12:00 |

I-18 Dimitris MarisAsymptotic Analysis on a TMDD model: Control of the processWednesday 10:30-12:00 |

I-19 Emma MartinUsing mixed effects modelling improves detection of drug-gene interactions in mouse trialsWednesday 10:30-12:00 |

I-20 Paolo MazzeiTranslational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase IWednesday 10:30-12:00 |

I-21 Nicola MelilloMultiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models.Wednesday 10:30-12:00 |

I-22 Sandrine MicallefEvaluation of tumor kinetics metrics as early endpoint to support decision making in early drug developmentWednesday 10:30-12:00 |

I-23 Joske MillecamA new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomicsWednesday 10:30-12:00 |

I-24 Jonathan MochelOne Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean NetworkWednesday 10:30-12:00 |

I-25 Daniel MojApplication of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adultsWednesday 10:30-12:00 |

I-26 Tadakatsu NakamuraPopulation Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic NephropathyWednesday 10:30-12:00 |

I-27 Srividya NeelakantanPopulation Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All AgesWednesday 10:30-12:00 |

I-28 Asuka SuzukiA Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese SubjectsWednesday 10:30-12:00 |

I-29 Thu Thuy NguyenPopulation pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool childrenWednesday 10:30-12:00 |

I-30 Rikard NordgrenCalling C functions from NONMEMWednesday 10:30-12:00 |

I-31 Ana NovakovicA longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS)Wednesday 10:30-12:00 |

I-32 Kayode OgungbenroSparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia AWednesday 10:30-12:00 |

I-33 Boram OhkPopulation Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite Wednesday 10:30-12:00 |

I-34 Olafuyi Olusola The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin.Wednesday 10:30-12:00 |

I-35 Sean OosterholtPKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastomaWednesday 10:30-12:00 |

I-36 - -Investigation of Bayesian inference in predicting tissue concentrations using RStanWednesday 10:30-12:00 |

I-37 Maria PanselinaDose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatricsWednesday 10:30-12:00 |

I-38 Sang-In ParkPopulation pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal functionWednesday 10:30-12:00 |

I-39 Zinnia Parra-GuillenExploring the impact of study design on unperturbed tumour growth inhibition modellingWednesday 10:30-12:00 |

I-40 Christophe PassotIn-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritisWednesday 10:30-12:00 |

I-41 Dimple PatelInforming modeling and clinical trial simulation using the real world data: data content, quality and availability assessmentWednesday 10:30-12:00 |

I-42 Dimitrios PatsatzisConstruction and evaluation of "global" Micahelis-Menten reduced modelsWednesday 10:30-12:00 |

I-43 Sophie PeignéHow to handle non-linearity in absorption: a case study in oncology Wednesday 10:30-12:00 |

I-44 Nathalie PerdaemsMulti-species translational PK/PD modelling in type 2 diabetes Wednesday 10:30-12:00 |

I-45 Belén Pérez SolansModelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapyWednesday 10:30-12:00 |

I-46 Jonás Samuel Pérez-BlancoPopulation PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonistWednesday 10:30-12:00 |

I-47 Carlos Perez-RuixoIdentifying lack of adherence to antipsychotic treatment using plasma concentrations measurementsWednesday 10:30-12:00 |

I-48 Chiara PianaA model-based approach to extrapolate drug-drug interactions from rats to humansWednesday 10:30-12:00 |

I-49 Philippe PierrillasApplication of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncologyWednesday 10:30-12:00 |

I-50 Nikhil PillaiEstimating Nonlinear Dynamic Systems in Pharmacology using Chaos SynchronizationWednesday 10:30-12:00 |

I-51 Italo PoggesiA Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase Wednesday 10:30-12:00 |

I-52 Sebastian PolakPhysiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment.Wednesday 10:30-12:00 |

I-53 Manuel Prado-VelascoPBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary resultsWednesday 10:30-12:00 |

I-54 Tim PreijersPopulation pharmacokinetic analysis of perioperative factor IX dosing in hemophilia BWednesday 10:30-12:00 |

I-55 Angelica QuartinoCrenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3Wednesday 10:30-12:00 |

I-56 Christian Hove ClaussenPharmTeX: a LaTeX-based open-source platform for automated reporting workflowWednesday 10:30-12:00 |

I-57 Theo ReijmersPopulation PK Modeling of Dapivirine released from Vaginal RingsWednesday 10:30-12:00 |

I-58 Didier RenardLabel extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adultsWednesday 10:30-12:00 |

I-59 Christer RimmlerDevelopment of a PBPK model to predict the pharmacokinetics of cefuroxime during surgeryWednesday 10:30-12:00 |

I-60 Christelle RodriguesPopulation pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic childrenWednesday 10:30-12:00 |

I-61 Amin RostamiPredicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK modelWednesday 10:30-12:00 |

I-62 Hauke RuehsExposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modellingWednesday 10:30-12:00 |

I-63 Leire Ruiz CerdáModeling of Interferon effector pathway after viral infectionWednesday 10:30-12:00 |

I-64 Alberto RussuDose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarityWednesday 10:30-12:00 |

I-65 Sunae RyuPopulation pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairmentWednesday 10:30-12:00 |

I-66 Muhammad Waqas SadiqA model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices Wednesday 10:30-12:00 |

I-68 Mark SaleApplication of global search methods for parameter estimation in models with poorly defined objective function surfacesWednesday 10:30-12:00 |

I-69 Franziska Schädeli StarkAssessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special populationWednesday 10:30-12:00 |

I-70 Stein SchalkwijkPlacental Transfer of Darunavir and Simulation of Fetal ExposureWednesday 10:30-12:00 |